

Literaturverzeichnis

1. UICC (1994). Manual of Clinical Oncology. Springer-Verlag; 1994.
2. Townsend CM. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. W B Saunders Co; 2001.
3. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. International Journal of Cancer 1999; 83:18-29.
4. The World Health Report 1997--conquering suffering, enriching humanity. World Health Forum 1997; 18:248-260.
5. Feldman. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2002.
6. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland - Häufigkeiten und Trends (5. überarbeitete, aktualisierte Ausgabe). Saarbrücken: 2006.
7. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52:6735-6740.
8. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T, Ruiz B. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50:4737-4740.
9. Fox JG, Wang TC. Helicobacter pylori - not a good bug after all. New England Journal of Medicine 2001; 345:829-832.
10. Robbins. Robbins Pathologic Basis of Disease. W. B. Saunders Company; 2003.
11. Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. J Surg Oncol 2005; 90:114-133.
12. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333:32-41.
13. Staszewski J. Smoking and cancer of the alimentary tract in Poland. Br J Cancer 1969; 23:247-253.

14. Imai T, Kubo T, Watanabe H. Chronic gastritis in Japanese with reference to high incidence of gastric carcinoma. *J Natl Cancer Inst* 1971; 47:179-195.
15. Matsukura N, Suzuki K, Kawachi T, Aoyagi M, Sugimura T, Kitaoka H, Numajiri H, Shiota A, Itabashi M, Hirota T. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. *J Natl Cancer Inst* 1980; 65:231-240.
16. Vallot T. [*Helicobacter pylori* and gastroduodenal disease]. *Rev Prat* 1994; 44:894-899.
17. Correa P, Chen VW. Gastric cancer. *Cancer Surv* 1994; 19-20:55-76.
18. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999; 340:825-831.
19. Kondo K. Duodenogastric reflux and gastric stump carcinoma. *Gastric Cancer* 2002; 5:16-22.
20. von Holstein CS. Long-term prognosis after partial gastrectomy for gastroduodenal ulcer. *World J Surg* 2000; 24:307-314.
21. Byrne JP, Attwood SE. Duodenogastric reflux and cancer. *Hepatogastroenterology* 1999; 46:74-85.
22. Mukaisho K, Miwa K, Kumagai H, Bamba M, Sugihara H, Hattori T. Gastric carcinogenesis by duodenal reflux through gut regenerative cell lineage. *Dig Dis Sci* 2003; 48:2153-2158.
23. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. *Cancer* 2003; 98:940-948.
24. Cristallini EG, Ascani S, Bolis GB. Association between histologic type of polyp and carcinoma in the stomach. *Gastrointest Endosc* 1992; 38:481-484.
25. Hohenberger P, Gretschel S. Gastric cancer. *Lancet* 2003; 362:305-315.
26. AIRD I, BENTALL HH, ROBERTS JA. A relationship between cancer of stomach and the ABO blood groups. *Br Med J* 1953; 1:799-801.

27. Mecklin JP, Nordling S, Saario I. Carcinoma of the stomach and its heredity in young patients. *Scand J Gastroenterol* 1988; 23:307-311.
28. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. *Cancer* 1993; 71:677-685.
29. Zwick A, Munir M, Ryan CK, Gian J, Burt RW, Leppert M, Spirio L, Chey WY. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. *Gastroenterology* 1997; 113:659-663.
30. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. *Semin Oncol* 1996; 23:281-291.
31. Zhang L, Blot WJ, You WC, Chang YS, Liu XQ, Kneller RW, Zhao L, Liu WD, Li JY, Jin ML, . Serum micronutrients in relation to pre-cancerous gastric lesions. *Int J Cancer* 1994; 56:650-654.
32. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; 345:784-789.
33. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991; 325:1132-1136.
34. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. *N Engl J Med* 1991; 325:1127-1131.
35. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. *BMJ* 1991; 302:1302-1305.
36. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. *Lancet* 1996; 348:150-154.
37. Fukao A, Tsubono Y, Tsuji I, Hlsamichi S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. *Int J Cancer* 1995; 60:45-48.
38. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. *CA Cancer J Clin* 1998; 48:6-29.

39. Aoki K, KMHNeal. Death Rates for Malignant Neoplasms for Selected Sites by Sex and Five-Year Age Group in 33 Countries 1953-57 to 1983-87. The University of Nagoya Coop Press; 1992.
40. Forman D. Review article: oesophago-gastric adenocarcinoma -- an epidemiological perspective. *Aliment Pharmacol Ther* 2004; 20 Suppl 5:55-60.
41. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. *Semin Oncol* 2004; 31:450-464.
42. Tytgat GN, Bartelink H, Bernardis R, Giaccone G, van Lanschot JJ, Offerhaus GJ, Peters GJ. Cancer of the esophagus and gastric cardia: recent advances. *Dis Esophagus* 2004; 17:10-26.
43. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. *Ann Oncol* 2003; 14 Suppl 2:ii31-ii36.
44. Keller G. Hereditary aspects of gastric cancer. *Pathologica* 2002; 94:229-233.
45. Friedlander ML, Hedley DW, Taylor IW. Clinical and biological significance of aneuploidy in human tumours. *J Clin Pathol* 1984; 37:961-974.
46. Nanus DM, Kelsen DP, Niedzwiecki D, Chapman D, Brennan M, Cheng E, Melamed M. Flow cytometry as a predictive indicator in patients with operable gastric cancer. *J Clin Oncol* 1989; 7:1105-1112.
47. Setälä LP, Nordling S, Kosma VM, Lipponen PK, Eskelinen MJ, Hollmen SM, Syrjänen KJ, Alhava EM. Comparison of DNA ploidy and S-phase fraction with prognostic factors in gastric cancer. *Anal Quant Cytol Histol* 1997; 19:524-532.
48. Esteban F, de Vega DS, Garcia R, Rodriguez R, Manzanares J, Almeida A, Tamames S. DNA content by flow cytometry in gastric carcinoma: pathology, ploidy and prognosis. *Hepatogastroenterology* 1999; 46:2039-2043.
49. Wright PA, Quirke P, Attanoos R, Williams GT. Molecular pathology of gastric carcinoma: progress and prospects. *Hum Pathol* 1992; 23:848-859.
50. Rhyu MG. Genetic events underlying morphological complexity of gastric carcinoma. *J Korean Med Sci* 1998; 13:339-349.

51. Rhyu MG, Park WS, Meltzer SJ. Microsatellite instability occurs frequently in human gastric carcinoma. *Oncogene* 1994; 9:29-32.
52. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. *Semin Oncol* 1996; 23:307-315.
53. Ottini L, Palli D, Falchetti M, D'Amico C, Amorosi A, Saieva C, Calzolari A, Cimoli F, Tatarelli C, De Marchis L, Masala G, Mariani-Costantini R, Cama A. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. *Cancer Res* 1997; 57:4523-4529.
54. Tahara E. Molecular mechanism of stomach carcinogenesis. *J Cancer Res Clin Oncol* 1993; 119:265-272.
55. Hussain SP, Harris CC. Molecular epidemiology of human cancer. *Recent Results Cancer Res* 1998; 154:22-36.
56. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. *Int J Cancer* 1992; 50:859-862.
57. Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. *J Pathol* 1993; 170:279-283.
58. Brito MJ, Williams GT, Thompson H, Filipe MI. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. *Gut* 1994; 35:1697-1700.
59. Miracco C, Spina D, Vindigni C, Filipe MI, Tosi P. Cell proliferation patterns and p53 expression in gastric dysplasia. *Int J Cancer* 1995; 62:149-154.
60. Craanen ME, Blok P, Dekker W, Offerhaus GJ, Tytgat GN. Chronology of p53 protein accumulation in gastric carcinogenesis. *Gut* 1995; 36:848-852.
61. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. *Am J Pathol* 1994; 144:511-517.
62. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T. p21 expression is a prognostic factor in patients with p53-negative gastric cancer. *Cancer Lett* 2000; 148:181-188.

63. Fox JG, Li X, Cahill RJ, Andrutis K, Rustgi AK, Odze R, Wang TC. Hypertrophic gastropathy in *Helicobacter felis*-infected wild-type C57BL/6 mice and p53 hemizygous transgenic mice. *Gastroenterology* 1996; 110:155-166.
64. Cahill RJ, Kilgallen C, Beattie S, Hamilton H, O'Morain C. Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. *Gut* 1996; 38:177-181.
65. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. *Dig Dis Sci* 1998; 43:964-970.
66. Kaye PV, Radebold K, Isaacs S, Dent DM. Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. *Eur J Surg Oncol* 2000; 26:39-43.
67. Maeda K, Kang SM, Onoda N, Ogawa M, Kato Y, Sawada T, Chung KH. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. *Cancer* 1999; 86:566-571.
68. Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis. *Br J Cancer* 1999; 79:1255-1261.
69. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988; 319:525-532.
70. Nakatsuru S, Yanagisawa A, Ichii S, Tahara E, Kato Y, Nakamura Y, Horii A. Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. *Hum Mol Genet* 1992; 1:559-563.
71. Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. *Gastroenterology* 1994; 106:1584-1588.
72. Tamura G, Maesawa C, Suzuki Y, Tamada H, Satoh M, Ogasawara S, Kashiwaba M, Satodate R. Mutations of the APC gene occur during early stages of gastric adenoma development. *Cancer Res* 1994; 54:1149-1151.

73. Wu MS, Shun CT, Wang HP, Sheu JC, Lee WJ, Wang TH, Lin JT. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and *Helicobacter pylori* infection. *Gastroenterology* 1997; 112:1457-1465.
74. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998; 392:402-405.
75. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grudei T, Becker KF, Mueller J, Siewert JR, Hofler H. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. *Am J Pathol* 1999; 155:337-342.
76. Zheng ZH, Sun XJ, Zhou HT, Shang C, Ji H, Sun KL. Analysis of metastasis suppressing function of E-cadherin in gastric cancer cells by RNAi. *World J Gastroenterol* 2005; 11:2000-2003.
77. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. *Gastric Cancer* 2005; 8:86-94.
78. Kawanishi K, Doki Y, Shiozaki H, Yano M, Inoue M, Fukuchi N, Utsunomiya T, Watanabe H, Monden M. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. *Am J Clin Pathol* 2000; 113:266-274.
79. Shinmura K, Kohno T, Takahashi M, Sasaki A, Ochiai A, Guilford P, Hunter A, Reeve AE, Sugimura H, Yamaguchi N, Yokota J. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. *Carcinogenesis* 1999; 20:1127-1131.
80. Stone J, Bevan S, Cunningham D, Hill A, Rahman N, Peto J, Marossy A, Houlston RS. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. *Br J Cancer* 1999; 79:1935-1937.
81. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E-cadherin mediated adhesion system in cancer cells. *Cancer* 1996; 77:1605-1613.
82. Streit M, Schmidt R, Hilgenfeld RU, Thiel E, Kreuser ED. Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. *Recent Results Cancer Res* 1996; 142:19-50.

83. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. *Oncology* 1999; 57:131-137.
84. Tannapfel A, Yasui W, Yokozaki H, Wittekind C, Tahara E. Effect of hepatocyte growth factor on the expression of E- and P-cadherin in gastric carcinoma cell lines. *Virchows Arch* 1994; 425:139-144.
85. Wu ZY, Zhan WH, Li JH, He YL, Wang JP, Lan P, Peng JS, Cai SR. Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis. *World J Gastroenterol* 2005; 11:3139-3143.
86. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. *Cancer* 1996; 77:858-863.
87. Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, Taniguchi K, Miwa K, Ohoyama S, Sugiyama K, Sasaki T. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. *Clin Cancer Res* 1999; 5:1823-1829.
88. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. *Cancer Lett* 2000; 153:7-12.
89. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. *J Clin Oncol* 2006; 24:228-240.
90. Park WS, Oh RR, Kim YS, Park JY, Shin MS, Lee HK, Lee SH, Yoo NJ, Lee JY. Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. *APMIS* 2000; 108:195-200.
91. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. *Cancer* 1999; 85:1894-1902.

92. Tahara E, Yasui W, Taniyama K, Ochiai A, Yamamoto T, Nakajo S, Yamamoto M. Ha-ras oncogene product in human gastric carcinoma: correlation with invasiveness, metastasis or prognosis. *Jpn J Cancer Res* 1986; 77:517-522.
93. Ueki T, Koji T, Tamiya S, Nakane PK, Tsuneyoshi M. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. *J Pathol* 1995; 177:353-361.
94. Yoshida K, Yasui W, Ito H, Tahara E. Growth factors in progression of human esophageal and gastric carcinomas. *Exp Pathol* 1990; 40:291-300.
95. Akimoto S, Ochiai A, Inomata M, Hirohashi S. Expression of cadherin-catenin cell adhesion molecules, phosphorylated tyrosine residues and growth factor receptor-tyrosine kinases in gastric cancers. *Jpn J Cancer Res* 1998; 89:829-836.
96. Suzuki T, Tsuda T, Haruma K, Yoshihara M, Sumii K, Kajiyama G. Growth of human gastric carcinomas and expression of epidermal growth factor, transforming growth factor-alpha, epidermal growth factor receptor and p185c-erbB-2. *Oncology* 1995; 52:385-391.
97. Saegusa M, Takano Y, Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. *J Cancer Res Clin Oncol* 1995; 121:357-363.
98. Schwartz GK. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. *Semin Oncol* 1996; 23:316-324.
99. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS, Sato E. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. *Clin Cancer Res* 1998; 4:2605-2614.
100. Schwartz GK, Wang H, Lampen N, Altorki N, Kelsen D, Albino AP. Defining the invasive phenotype of proximal gastric cancer cells. *Cancer* 1994; 73:22-27.
101. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. *Cancer Res* 1994; 54:422-426.
102. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. *Cancer Res* 1997; 57:1276-1280.

103. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. *Am J Gastroenterol* 1999; 94:451-455.
104. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K, Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. *Am J Physiol* 1998; 274:G1061-G1067.
105. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW, Jr. Aspirin use and risk of fatal cancer. *Cancer Res* 1993; 53:1322-1327.
106. Yamamoto H, Itoh F, Fukushima H, Hinoda Y, Imai K. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. *Int J Cancer* 1999; 84:400-403.
107. Holland, Frei. *Cancer Medicine* 6. 2003.
108. Sokoloff B. Predisposition to cancer in the Bonaparte family. *Am J Surg* 1938; 1938:673-678.
109. Creagan ET, Fraumeni JF, Jr. Familial gastric cancer and immunologic abnormalities. *Cancer* 1973; 32:1325-1331.
110. MACKLIN MT. Inheritance of cancer of the stomach and large intestine in man. *J Natl Cancer Inst* 1960; 24:551-571.
111. VIDEBAEK A, MOSBECH J. The aetiology of gastric carcinoma elucidated by a study of 302 pedigrees. *Acta Med Scand* 1954; 149:137-159.
112. Zanghieri G, Di Gregorio C, Sacchetti C, Fante R, Sassatelli R, Cannizzo G, Carriero A, Ponz dL. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. *Cancer* 1990; 66:2047-2051.
113. Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, Oliveira C, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE. Familial gastric cancer: overview and guidelines for management. *J Med Genet* 1999; 36:873-880.

114. Gayther SA, Goringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BA, Caldas C. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Cancer Res* 1998; 58:4086-4089.
115. Guilford PJ, Hopkins JB, Grady WM, Markowitz SD, Willis J, Lynch H, Rajput A, Wiesner GL, Lindor NM, Burgart LJ, Toro TT, Lee D, Limacher JM, Shaw DW, Findlay MP, Reeve AE. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. *Hum Mutat* 1999; 14:249-255.
116. Bresciani C, Perez RO, Gama-Rodrigues J. Familial gastric cancer. *Arq Gastroenterol* 2003; 40:114-117.
117. Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Jarvinen HJ. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. *Int J Cancer* 1997; 74:551-555.
118. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. *J Natl Cancer Inst* 1998; 90:1039-1071.
119. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. *N Engl J Med* 2001; 344:1904-1909.
120. Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. *Hum Mol Genet* 1999; 8:607-610.
121. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR, Hofler H. Diffuse Type Gastric and Lobular Breast Carcinoma in a Familial Gastric Cancer Patient with an E-Cadherin Germline Mutation. *Am J Pathol* 1999; 155:337-342.
122. Yoon KA, Ku JL, Yang HK, Kim WH, Park SY, Park JG. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. *J Hum Genet* 1999; 44:177-180.

123. Yabuta T, Shinmura K, Tani M, Yamaguchi S, Yoshimura K, Katai H, Nakajima T, Mochiki E, Tsujinaka T, Takami M, Hirose K, Yamaguchi A, Takenoshita S, Yokota J. E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer. *Int J Cancer* 2002; 101:434-441.
124. Oliveira C, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC, Kiviluoto T, Aaltonen L, Jackson CE, Seruca R, Caldas C. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. *Hum Mutat* 2002; 19:510-517.
125. Humar B, Toro T, Graziano F, Muller H, Dobbie Z, Kwang-Yang H, Eng C, Hampel H, Gilbert D, Winship I, Parry S, Ward R, Findlay M, Christian A, Tucker M, Tucker K, Merriman T, Guilford P. Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. *Hum Mutat* 2002; 19:518-525.
126. Keller G, Vogelsang H, Becker I, Plaschke S, Ott K, Suriano G, Mateus AR, Seruca R, Biedermann K, Huntsman D, Doring C, Holinski-Feder E, Neutzling A, Siewert JR, Hofler H. Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. *J Med Genet* 2004; 41:e89.
127. Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, Berx G, Sobrinho-Simoes M. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. *Lab Invest* 1999; 79:459-465.
128. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. *Gut* 2004; 53:814-820.
129. Wang HD, Ren J, Zhang L. CDH1 germline mutation in hereditary gastric carcinoma. *World J Gastroenterol* 2004; 10:3088-3093.
130. Seruca R, Carneiro F, Castedo S, David L, Lopes C, Sobrinho-Simoes M. Familial gastric polyposis revisited. Autosomal dominant inheritance confirmed. *Cancer Genet Cytogenet* 1991; 53:97-100.
131. Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF, Martin J, Birch JM, Evans DG. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. *J Med Genet* 1995; 32:942-945.

132. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, . Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. *N Engl J Med* 1992; 326:1301-1308.
133. Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Kawa-ha K, Hirata Y, Mizoguchi H, Sugimura T, Terada M, Yokota J. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. *J Natl Cancer Inst* 1992; 84:703-707.
134. Horio Y, Suzuki H, Ueda R, Koshikawa T, Sugiura T, Ariyoshi Y, Shimokata K, Takahashi T, Takahashi T. Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. *Oncogene* 1994; 9:1231-1235.
135. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. *Am J Pathol* 1997; 150:1-13.
136. Robert J.Mayer. *Harrison's Principles of Internal Medicine*. McGraw-Hill; 2001.
137. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Jr., Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. *Ann Surg* 1993; 218:583-592.
138. Sobotta JPRPR. *Atlas der Anatomie des Menschen*. Urban & Fischer; 2004.
139. Bottcher K, Roder JD, Busch R, Fink U, Siewert JR, Hermanek P, Meyer HJ. [The epidemiology of stomach carcinoma from the surgical viewpoint. The results of the German Stomach Carcinoma Study 1992. The German Stomach Carcinoma Study Group]. *Dtsch Med Wochenschr* 1993; 118:729-736.
140. UICC (1992). *TNM Classification of Malignant Tumours*, 4th Edition. Springer-Verlag; 1992.
141. UICC (1997). *TNM Classification of Malignant Tumours*, 5th Edition. 1997.
142. UICC (2002). *TNM Classification of Malignant Tumours*, 6th Edition. Sobin, L. H. and Wittekind, C. 2002. Berlin Heidelberg New York, Wiley-Liss.

143. Wittekind C, Greene FL, Hutter RV, Klimpfinger M, Sobin LH. TNM Atlas: Illustrated Guide to the TNM Classification of Malignant Tumours. Springer; 2006.
144. Hunt S, Doherty GM. Current Surgical Diagnosis & Treatment. Norwalk, Connecticut, USA: Appleton & Lange; 2003.
145. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition -. Gastric Cancer 1998; 1:10-24.
146. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;31-49.
147. Fenoglio-Preiser CM, Noffsinger AE, Belli J, Stemmermann GN. Pathologic and phenotypic features of gastric cancer. Semin Oncol 1996; 23:292-306.
148. Munoz N, Correa P, Cuello C, Duque E. Histologic types of gastric carcinoma in high- and low-risk areas. Int J Cancer 1968; 3:809-818.
149. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. New York: Garland Publishing Inc.; 1994.
150. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71:1368-1383.
151. Castronovo V. Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion Metastasis 1993; 13:1-30.
152. Mareel MM, Van Roy FM, De Baetselier P. The invasive phenotypes. Cancer Metastasis Rev 1990; 9:45-62.
153. Vielhaber A. Einfluß der Zell-Zell- und Zell-Basalmembran-Interaktion auf das Invasions- und Metastasierungsverhalten von Magenkarzinomen. 2001.
154. Orita H, Korenaga D, Maehara Y, Baba H, Sugimachi K. Laminin distribution patterns are closely related to liver metastasis in gastric cancer. Cancer 1993; 71:1201-1206.

155. David L, Nesland JM, Holm R, Sobrinho-Simoes M. Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. An immunohistochemical study of 87 patients. *Cancer* 1994; 73:518-527.
156. Inada K, Shimokawa K, Ikeda T, Ozeki Y. The clinical significance of venous invasion in cancer of the stomach. *Jpn J Surg* 1990; 20:545-552.
157. Tanaka A, Watanabe T, Okuno K, Yasutomi M. Perineural invasion as a predictor of recurrence of gastric cancer. *Cancer* 1994; 73:550-555.
158. Duarte I, Llanos O. Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. *Hum Pathol* 1981; 12:237-242.
159. Esaki Y, Hirayama R, Hirokawa K. A comparison of patterns of metastasis in gastric cancer by histologic type and age. *Cancer* 1990; 65:2086-2090.
160. Goseki N, Takizawa T, Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. *Gut* 1992; 33:606-612.
161. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. *World J Surg* 1987; 11:418-425.
162. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. *Cancer* 1993; 72:2089-2097.
163. Hermanek P. Disseminated tumor cells versus micrometastasis: definitions and problems. *Anticancer Res* 1999; 19:2771-2774.
164. Sanson M, Cited by Papac R. Fait remarquable de diathèse cancéreuse. *Gaz Med de Paris* 1834.
165. Ashwort TR, Cited by Abati A. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. *Aust Med J* 1896.
166. Ryall A. Technique of Cancer Operations. *British Medical Journal* 1908.
167. CHRISTOPHERSON WM. Cancer Cells in the peripheral Blood: A second Look. *Acta Cytol* 1965; 86:169-174.
168. Peckham MJ, Pinedo HM, Veronesi U. *Oxford Textbook of Oncology*. Oxford University Press; 1995.

169. Devita VT, Hellman S, Rosenberg SA. *Cancer: Principles and Practice of Oncology*. Lippincott Williams & Wilkins Publishers; 2001.
170. Abati A, Liotta LA. Looking forward in diagnostic pathology: the molecular superhighway. *Cancer* 1996; 78:1-3.
171. Hermanek P, Hutter RV, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. *Cancer* 1999; 86:2668-2673.
172. Combaret V, Favrot MC, Bailly C, Philip I, Zucker JM, Philip T. [Value of immunological analysis for the detection of residual neuroblasts in the bone marrow]. *Bull Cancer* 1988; 75:79-82.
173. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, Riethmuller G. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. *Lancet* 1996; 347:649-653.
174. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. *N Engl J Med* 2000; 342:525-533.
175. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. *J Clin Oncol* 1991; 9:1749-1756.
176. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic-Significance of Micrometastatic Tumor-Cells in Bone-Marrow of Colorectal-Cancer Patients. *Lancet* 1992; 340:685-689.
177. Thorban S, Rosenberg R, Busch R, Roder RJ. Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. *Br J Cancer* 2000; 83:35-39.
178. Juhl H, Stritzel M, Wroblewski A, Henne-Bruns D, Kremer B, Schmiegel W, Neumaier M, Wagener C, Schreiber HW, Kalthoff H. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. *Int J Cancer* 1994; 57:330-335.

179. Riesenberger R, Oberneder R, Kriegsmair M, Epp M, Bitzer U, Hofstetter A, Braun S, Riethmuller G, Pantel K. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. *Histochemistry* 1993; 99:61-66.
180. Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J, Riethmuller G. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. *Eur J Cancer* 1991; 27:1461-1465.
181. Harrison LE, Choe JK, Goldstein M, Meridian A, Kim SH, Clarke K. Prognostic significance of immunohistochemical micrometastases in node negative gastric cancer patients. *J Surg Oncol* 2000; 73:153-157.
182. Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y, Kohnoe S, Sugimachi K. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. *Surgery* 1996; 119:397-402.
183. Ishida K, Katsuyama T, Sugiyama A, Kawasaki S. Immunohistochemical evaluation of lymph node micrometastases from gastric carcinomas. *Cancer* 1997; 79:1069-1076.
184. Cai J, Ikeguchi M, Tsujitani S, Maeta M, Kaibara N. Micrometastasis in lymph nodes of mucosal gastric cancer. *Gastric Cancer* 2000; 3:91-96.
185. Fukagawa T, Sasako M, Mann GB, Sano T, Katai H, Maruyama K, Nakanishi Y, Shimoda T. Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma. *Cancer* 2001; 92:753-760.
186. Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber HW, Schmiegel W, Henne-Bruns D, Kremer B, Juhl H. Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. *Annals of Surgery* 1998; 227:372-379.
187. Vogel P, Ruschoff J, Kummel S, Zirngibl H, Hofstadter F, Hohenberger W, Jauch KW. Prognostic value of microscopic peritoneal dissemination: comparison between colon and gastric cancer. *Dis Colon Rectum* 2000; 43:92-100.
188. Nakanishi H, Kodera Y, Yamamura Y, Ito S, Kato T, Ezaki T, Tatematsu M. Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcycler. *Int J Cancer* 2000; 89:411-417.

189. Yonemura Y, Fujimura T, Ninomiya I, Kim BS, Bandou E, Sawa T, Kinoshita K, Endo Y, Sugiyama K, Sasaki T. Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. *Clin Cancer Res* 2001; 7:1647-1653.
190. Gross HJ, Verwer B, Houck D, Hoffman RA, Recktenwald D. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10^{-7} . *Proc Natl Acad Sci U S A* 1995; 92:537-541.
191. Aihara T, Noguchi S, Ishikawa O, Furukawa H, Hiratsuka M, Ohigashi H, Nakamori S, Monden M, Imaoka S. Detection of pancreatic and gastric cancer cells in peripheral and portal blood by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. *Int J Cancer* 1997; 72:408-411.
192. Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U, Henne-Bruns D, Kremer B, Kalthoff H. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. *Cancer Res* 1997; 57:3106-3110.
193. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. *Proc Natl Acad Sci U S A* 1998; 95:4589-4594.
194. Weitz J, Kienle P, Magener A, Koch M, Schrodell A, Willeke F, Autschbach F, Lacroix J, Lehnert T, Herfarth C, von Knebel DM. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. *Clin Cancer Res* 1999; 5:1830-1836.
195. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. *Cytotherapy* 1999; 1:377-388.
196. Chausovsky G, Luchansky M, Figer A, Shapira J, Gottfried M, Novis B, Bogelman G, Zemer R, Zimlichman S, Klein A. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. *Cancer* 1999; 86:2398-2405.

197. Majima T, Ichikura T, Takayama E, Chochi K, Mochizuki H. Detecting circulating cancer cells using reverse transcriptase- polymerase chain reaction for cytokeratin mRNA in peripheral blood from patients with gastric cancer. *Jpn J Clin Oncol* 2000; 30:499-503.
198. Zippelius A, Pantel K. RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. *Ann N Y Acad Sci* 2000; 906:110-123.
199. Kim SJ, Ikeda N, Shiba E, Takamura Y, Noguchi S. Detection of breast cancer micrometastases in peripheral blood using immunomagnetic separation and immunocytochemistry. *Breast Cancer* 2001; 8:63-69.
200. Rosenberg R, Nekarda H, Thorban S, Siewert JR. [Minimal residual disease in gastrointestinal tumors: tumor detection in bone marrow, blood and lymph nodes]. *Acta Med Austriaca Suppl* 2002; 59:42-53.
201. Illert B, Otto C, Braendlein S, Thiede A, Timmermann W. Optimization of a metastasizing human gastric cancer model in nude mice. *Microsurgery* 2003; 23:508-512.
202. Illert B, Otto C, Thiede A, Timmermann W. Detection of disseminated tumor cells in nude mice with human gastric cancer. *Clin Exp Metastasis* 2003; 20:549-554.
203. Hosch S, Kraus J, Scheunemann P, Izbicki JR, Schneider C, Schumacher U, Witter K, Speicher MR, Pantel K. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. *Cancer Res* 2000; 60:6836-6840.
204. Pretlow TG, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL, Murphy JR, Markowitz SD, Jamison JM, Summers JL, Hamlin CR, MacLennan GT, Resnick MI, Pretlow TP, Connell CF. Prostate cancer and other xenografts from cells in peripheral blood of patients. *Cancer Res* 2000; 60:4033-4036.
205. Hosch SB, Braun S, Pantel K. Characterization of disseminated tumor cells. *Semin Surg Oncol* 2001; 20:265-271.
206. Hawes D, Neville AM, Cote RJ. Detection of occult metastasis in patients with breast cancer. *Semin Surg Oncol* 2001; 20:312-318.
207. Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Hoechtlen-Vollmar W, Schlimok G, Weckermann D, Oberneder R, Fanning E, . Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. *J Natl Cancer Inst* 1995; 87:1162-1168.

208. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmuller G, Pantel K. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. *Cancer Res* 1999; 59:241-248.
209. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmuller G. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. *Cancer Res* 1991; 51:4712-4715.
210. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. *J Natl Cancer Inst* 1993; 85:1419-1424.
211. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. *Proc Natl Acad Sci U S A* 1999; 96:4494-4499.
212. Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, Schlichting E, Qvist H, Naume B. Immunocytochemical detection of isolated epithelial cells in bone marrow: Non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. *Journal of Pathology* 1998; 185:427-434.
213. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001; 344:783-792.
214. Braun S, Hepp F, Kantenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. *Clin Cancer Res* 1999; 5:3999-4004.
215. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. *Cancer Res* 2001; 61:1890-1895.
216. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. *Br J Surg* 1997; 84:1651-1664.

217. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. *J Clin Oncol* 1995; 13:2084-2093.
218. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. *Nat Med* 1995; 1:1035-1039.
219. Yamamoto N, Kato Y, Yanagisawa A, Ohta H, Takahashi T, Kitagawa T. Predictive value of genetic diagnosis for cancer micrometastasis: histologic and experimental appraisal. *Cancer* 1997; 80:1393-1398.
220. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. *Gene* 1995; 159:43-47.
221. Sloane JP, Ormerod MG, Neville AM. Potential pathological application of immunocytochemical methods to the detection of micrometastases. *Cancer Res* 1980; 40:3079-3082.
222. Redding WH, Coombes RC, Monaghan P, Clink HM, Imrie SF, Dearnaley DP, Ormerod MG, Sloane JP, Gazet JC, Powles TJ, . Detection of micrometastases in patients with primary breast cancer. *Lancet* 1983; 2:1271-1274.
223. Osborne MP, Asina S, Wong GY, Old LJ, Cote RJ. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: sensitivity in a model system. *Cancer Res* 1989; 49:2510-2513.
224. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. *Cancer Res* 1991; 51:2706-2709.
225. Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel DM. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. *Clin Cancer Res* 1998; 4:343-348.
226. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, Tollenaar RA. Micrometastases and survival in stage II colorectal cancer. *N Engl J Med* 1998; 339:223-228.

227. Futamura M, Takagi Y, Koumura H, Kida H, Tanemura H, Shimokawa K, Saji S. Spread of colorectal cancer micrometastases in regional lymph nodes by reverse transcriptase-polymerase chain reactions for carcinoembryonic antigen and cytokeratin 20. *J Surg Oncol* 1998; 68:34-40.
228. Rosenberg R, Hoos A, Mueller J, Nekarda H. Impact of cytokeratin-20 and carcinoembryonic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer. *Br J Cancer* 2000; 83:1323-1329.
229. Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. *Ann Surg* 2000; 232:58-65.
230. Khan ZA, Jonas SK, Le Marer N, Patel H, Wharton RQ, Tarragona A, Ivison A, Allen-Mersh TG. P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. *Clin Cancer Res* 2000; 6:3499-3504.
231. Jauch KW, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, Eissner HJ, Riethmueller G, Schildberg FW. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. *J Clin Oncol* 1996; 14:1810-1817.
232. Mueller JD, Stein HJ, Oyang T, Natsugoe S, Feith M, Werner M, Rudiger SJ. Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction. *Cancer* 2000; 89:1874-1882.
233. Thorban S, Roder JD, Nekarda H, Funk A, Siewert JR, Pantel K. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. *J Natl Cancer Inst* 1996; 88:1222-1227.
234. Thorban S, Roder JD, Pantel K, Siewert JR. Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining. *Eur J Cancer* 1996; 32A:363-365.
235. Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. *N Engl J Med* 1997; 337:1188-1194.

236. Natsugoe S, Mueller J, Stein HJ, Feith M, Hofler H, Siewert JR. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. *Cancer* 1998; 83:858-866.
237. Luketich JD, Kassis ES, Shriver SP, Nguyen NT, Schauer PR, Weigel TL, Yousem SA, Siegfried JM. Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. *Ann Thorac Surg* 1998; 66:1715-1718.
238. Hosch SB, Knoefel WT, Metz S, Stoecklein N, Niendorf A, Broelsch CE, Izbicki JR. Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. *Pancreas* 1997; 15:154-159.
239. Demeure MJ, Doffek KM, Komorowski RA, Redlich PN, Zhu YR, Erickson BA, Ritch PS, Pitt HA, Wilson SD. Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation. *Surgery* 1998; 124:663-669.
240. Roder JD, Thorban S, Pantel K, Siewert JR. Micrometastases in bone marrow: prognostic indicators for pancreatic cancer. *World J Surg* 1999; 23:888-891.
241. Vogel I, Kruger U, Marxsen J, Soeth E, Kalthoff H, Henne-Bruns D, Kremer B, Juhl H. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. *Clin Cancer Res* 1999; 5:593-599.
242. Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. *Eur J Cancer* 2000; 36:1681-1694.
243. Ghossein RA, Carusone L, Bhattacharya S. Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. *Diagn Mol Pathol* 1999; 8:165-175.
244. Molino A, Colombatti M, Bonetti F, Zardini M, Pasini F, Perini A, Pelosi G, Tridente G, Veneri D, Cetto GL. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. *Cancer* 1991; 67:1033-1036.
245. Mattano LA, Jr., Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. *Cancer Res* 1992; 52:4701-4705.

246. Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. *Cancer* 1998; 82:1419-1442.
247. Wood DP, Jr., Banks ER, Humphreys S, Rangnekar VM. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. *J Histochem Cytochem* 1994; 42:505-511.
248. Noguchi S, Hiratsuka M, Furukawa H, Aihara T, Kasugai T, Tamura S, Imaoka S, Koyama H, Iwanaga T. Detection of gastric cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. *Jpn J Cancer Res* 1996; 87:650-654.
249. Leslie DS, Johnston WW, Daly L, Ring DB, Shpall EJ, Peters WP, Bast RC, Jr. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. *Am J Clin Pathol* 1990; 94:8-13.
250. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. *Br J Surg* 1996; 83:672-674.
251. Seeliger H, Spatz H, Jauch KW. Minimal residual disease in gastric cancer. *Recent Results Cancer Res* 2003; 162:79-87.
252. Sandler A, Nekarda H, Bottcher K, Fink U, Siewert JR. [Prognosis factors in stomach carcinoma]. *Dtsch Med Wochenschr* 1997; 122:794-800.
253. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. *Ann Surg* 1998; 228:449-461.
254. Okusa T, Nakane Y, Boku T, Takada H, Yamamura M, Hioki K, Yamamoto M. Quantitative analysis of nodal involvement with respect to survival rate after curative gastrectomy for carcinoma. *Surg Gynecol Obstet* 1990; 170:488-494.
255. Morgagni P, Saragoni L, Folli S, Gaudio M, Scarpi E, Bazzocchi F, Marra GA, Vio A. Lymph node micrometastases in patients with early gastric cancer: experience with 139 patients. *Ann Surg Oncol* 2001; 8:170-174.
256. Natsugoe S, Aikou T, Shimada M, Yoshinaka H, Takao S, Shimazu H, Matsushita Y. Occult lymph node metastasis in gastric cancer with submucosal invasion. *Surg Today* 1994; 24:870-875.

257. Siewert JR, Kestlmeier R, Busch R, Bottcher K, Roder JD, Muller J, Fellbaum C, Hofler H. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. *Br J Surg* 1996; 83:1144-1147.
258. Ikeguchi M, Fukuda K, Oka S, Hisamitsu K, Katano K, Tsujitani S, Kaibara N. Micro-lymph node metastasis and its correlation with cathepsin D expression in early gastric cancer. *J Surg Oncol* 2001; 77:188-194.
259. Choi HJ, Kim YK, Kim YH, Kim SS, Hong SH. Occurrence and prognostic implications of micrometastases in lymph nodes from patients with submucosal gastric carcinoma. *Ann Surg Oncol* 2002; 9:13-19.
260. Bottcher K, Roder JD, Siewert JR. [Value of radical lymph node dissection (compartment I and II) in stomach carcinoma]. *Zentralbl Chir* 1996; 121:131-138.
261. Siewert JR, Stein HJ, Bottcher K. [Lymphadenectomy in tumors of the upper gastrointestinal tract]. *Chirurg* 1996; 67:877-888.
262. Isozaki H, Okajima K, Fujii K. Histological evaluation of lymph node metastasis on serial sectioning in gastric cancer with radical lymphadenectomy. *Hepatogastroenterology* 1997; 44:1133-1136.
263. Cai J, Ikeguchi M, Maeta M, Kaibara N, Sakatani T. Clinicopathological value of immunohistochemical detection of occult involvement in pT3N0 gastric cancer. *Gastric Cancer* 1999; 2:95-100.
264. Gunven P, Maruyama K, Okabayashi K, Sasako M, Kinoshita T. Non-ominous micrometastases of gastric cancer. *Br J Surg* 1991; 78:352-354.
265. Zhang XW, Fan P, Yang HY, Yang L, Chen GY. [Significance of detecting disseminated tumor cells in peripheral blood of gastric and colorectal cancer patients]. *Zhonghua Zhong Liu Za Zhi* 2003; 25:66-69.
266. Ikeguchi M, Ohro S, Maeda Y, Fukuda K, Yamaguchi K, Shirai H, Kondo A, Tsujitani S, Kaibara N. Detection of cancer cells in the peripheral blood of gastric cancer patients. *Int J Mol Med* 2003; 11:217-221.
267. Lukyanchuk VV, Friess H, Kleeff J, Osinsky SP, Ayuni E, Candinas D, Roggo A. Detection of circulating tumor cells by cytokeratin 20 and prostate stem cell antigen RT-PCR in blood of patients with gastrointestinal cancers. *Anticancer Res* 2003; 23:2711-2716.

268. Ikeguchi M, Kaibara N. Detection of circulating cancer cells after a gastrectomy for gastric cancer. *Surg Today* 2005; 35:436-441.
269. Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Lee SW, Choi JH, Park YT, Mok YJ, Kim CS, Kim JS. Follow-up study of peripheral blood carcinoembryonic antigen mRNA using reverse transcription-polymerase chain reaction as an early marker of clinical recurrence in patients with curatively resected gastric cancer. *Am J Clin Oncol* 2005; 28:24-29.
270. Sumikura S, Ishigami S, Natsugoe S, Miyazono F, Tokuda K, Nakajo A, Okumura H, Matsumoto M, Hokita S, Aikou T. Disseminated cancer cells in the blood and expression of sialylated antigen in gastric cancer. *Cancer Lett* 2003; 200:77-83.
271. Miyazono F, Natsugoe S, Takao S, Tokuda K, Kijima F, Aridome K, Hokita S, Baba M, Eizuru Y, Aikou T. Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. *Ann Surg* 2001; 233:189-194.
272. Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, Riethmuller G, Pantel K. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. *J Clin Oncol* 1997; 15:2701-2708.
273. O'Sullivan GC, Collins JK, O'Brien F, Crowley B, Murphy K, Lee G, Shanahan F. Micrometastases in bone marrow of patients undergoing "curative" surgery for gastrointestinal cancer. *Gastroenterology* 1995; 109:1535-1540.
274. Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T, Ohno S, Ichiyoshi Y, Sugimachi K. Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. *Br J Cancer* 1996; 73:83-87.
275. Broll R, Lembcke K, Stock C, Zingler M, Duchrow M, Schimmelpenning H, Strik M, Muller G, Kujath P, Bruch HP. [Tumor cell dissemination in bone marrow and peritoneal cavity. An immunocytochemical study of patients with stomach or colorectal carcinoma]. *Langenbecks Arch Chir* 1996; 381:51-58.
276. Funke I, Fries S, Rolle M, Heiss MM, Untch M, Bohmert H, Schildberg FW, Jauch KW. Comparative analyses of bone marrow micrometastases in breast and gastric cancer. *Int J Cancer* 1996; 65:755-761.

277. Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. *Ann Surg* 1997; 226:736-744.
278. Allgayer H, Heiss MM, Riesenberger R, Grutzner KU, Tarabichi A, Babic R, Schildberg FW. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. *Cancer Res* 1997; 57:1394-1399.
279. Maehara Y, Hasuda S, Abe T, Oki E, Kakeji Y, Ohno S, Sugimachi K. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. *Clin Cancer Res* 1998; 4:2129-2134.
280. O'Sullivan GC, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, Walsh T, Collins JK, Shanahan F. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. *Gastroenterology* 1999; 116:543-548.
281. Kakeji Y., Maehara Y, Shibahara K., Hasuda S, Tokunaga E, Oki E., Sugimachi K. Clinical significance of micrometastasis in bone marrow of patients with gastric cancer and its relation to angiogenesis. *Gastric Cancer* 1999; 2:46-51.
282. Bonavina L, Soligo D, Quirici N, Bossolasco P, Cesana B, Lemberghini DG, Peracchia A. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. *Surgery* 2001; 129:15-22.
283. Heiss MM, Simon EH, Beyer BC, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, Allgayer H. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. *J Clin Oncol* 2002; 20:2005-2016.
284. De Manzoni G, Pelosi G, Pavanel F, Di Leo A, Pedrazzani C, Durante E, Cordiano C, Pasini F. The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients. *British Journal of Cancer* 2002; 86:1047-1051.
285. Macadam R, Sarela A, Wilson J, MacLennan K, Guillou P. Bone marrow micrometastases predict early post-operative recurrence following surgical resection of oesophageal and gastric carcinoma. *Eur J Surg Oncol* 2003; 29:450-454.

286. Matsunami K, Nakamura T, Oguma H, Kitamura Y, Takasaki K. Detection of bone marrow micrometastasis in gastric cancer patients by immunomagnetic separation. *Ann Surg Oncol* 2003; 10:171-175.
287. Jonas S, Weinrich M, Tullius SG, Al Abadi H, Steinbrich R, Radke C, Klupp J, Neuhaus P. Microscopic tumor cell dissemination in gastric cancer. *Surg Today* 2004; 34:101-106.
288. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. *J Clin Oncol* 1998; 16:557-566.
289. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* 1989; 339:58-61.
290. Folkman J. What is the evidence that tumors are angiogenesis dependent? *J Natl Cancer Inst* 1990; 82:4-6.
291. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. *Cancer Res* 1996; 56:2671-2676.
292. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. *J Am Stat Assoc* 1958; 53:457-481.
293. Cox CP. On estimating relative potency from quadratic log-dose response relationships. *Biometrics* 1972; 28:875-881.
294. Pantel K, Otte M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. *Semin Cancer Biol* 2001; 11:327-337.
295. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. *Cancer* 1997; 80:1803-1804.
296. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. *Cancer* 2002; 94:2511-2516.
297. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). *J Histochem Cytochem* 1984; 32:219-229.

298. Gerhartz HH, Schmetzer H. Detection of minimal residual disease in acute myeloid leukemia. *Leukemia* 1990; 4:508-516.
299. Moll R, Franke WW. Intermediate filaments and their interaction with membranes. The desmosome-cytokeratin filament complex and epithelial differentiation. *Pathol Res Pract* 1982; 175:146-161.
300. Soligo D, Lambertenghi-Delilieri G, Berti E, Polli N, Polli EE. Immunohistochemical evaluation of bone marrow involvement in hairy cell leukemia during interferon therapy. *Blut* 1987; 55:121-126.
301. Franke WW, Winter S, Schmid E, Sollner P, Hammerling G, Achtstatter T. Monoclonal cytokeratin antibody recognizing a heterotypic complex: immunological probing of conformational states of cytoskeletal proteins in filaments and in solution. *Exp Cell Res* 1987; 173:17-37.
302. Franke WW, Moll R. Cytoskeletal components of lymphoid organs. I. Synthesis of cytokeratins 8 and 18 and desmin in subpopulations of extrafollicular reticulum cells of human lymph nodes, tonsils, and spleen. *Differentiation* 1987; 36:145-163.
303. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. *J Natl Cancer Inst* 1994; 86:45-48.
304. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nat Med* 1995; 1:149-153.
305. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. *Nature* 1985; 315:301-305.
306. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. *Biochim Biophys Acta* 1994; 1198:165-184.
307. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW. The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. *Eur J Surg Oncol* 1996; 22:74-77.

308. Allgayer H, Heiss MM, Riesenberger R, Babic R, Jauch KW, Schildberg FW. Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA receptor and CK18: investigation of sensitivity and specificity of an immunogold/alkaline phosphatase double staining protocol. *J Histochem Cytochem* 1997; 45:203-212.
309. Andratschke M, Pauli C, Stein M, Chaubal S, Wollenberg B. MHC-class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer. *Anticancer Res* 2003; 23:1467-1471.